CSL (ASX:CSL) share price higher on US FDA flu vaccine news

CSL's shares are on form on Wednesday…

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is pushing higher on Wednesday morning.

At the time of writing, the biotherapeutics company's shares are up 1% to $319.78.

Why is the CSL share price rising?

The catalyst for the rise in the CSL share price this morning appears to have been the release of an announcement relating to its Seqirus business.

According to the release, the US Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) formulation of Audenz. This is the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.

Audenz was originally approved by the FDA in a single dose, prefilled syringe (PFS) presentation in 2020.

Management notes that FDA approval of the MDV presentation of Audenz marks an important milestone in Seqirus' pandemic preparedness efforts in partnership with Biomedical Advanced Research and Development Authority (BARDA).

BARDA is a component of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS).

Under the terms of the public-private partnership, which was established in 2009, Seqirus would position itself to deliver 150 million influenza vaccine doses to the U.S. government to support an influenza pandemic response within six months.

Seqirus executive director Marc Lacey commented:

Producing AUDENZ in multi-dose vials allows for increased speed and efficiency, which is absolutely critical to help protect public health in the case of an influenza pandemic.

According to the CDC, the influenza A(H5N1) virus is highly pathogenic and has high pandemic potential, so it's critical to be prepared. Seqirus is committed to partnering with key stakeholders to develop adequate and effective influenza pandemic preparedness plans.

What is pandemic influenza?

While similar to seasonal influenza, pandemic influenza is a contagious airborne respiratory disease which is unpredictable in timing and severity and has a higher risk of morbidity and mortality.

This is because there is likely to be little or no pre-existing immunity to the virus in the human population.

CSL notes that four influenza pandemics have occurred over the past century, with the 1918 pandemic being the most severe in recent history and estimated to have killed up to 50 million people worldwide. As such, this makes the work Seqirus is doing extremely important for the global population.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young smiling couple out hiking enjoy a view from the top of the mountains.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors enjoyed a rosy end to the trading week this Friday.

Read more »

A fun depiction of summer Santa Claus -- wearing red swimming trunks and Hawaiian shirt -- sitting in a deck chair on his laptop at the beach.
Opinions

2 ASX stocks on my naughty list this Christmas

Nothing but coal in the stockings of these disappointing companies.

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Record Highs

The multi-billion-dollar ASX tech share hitting new highs on broker bullishness

This ASX tech share darling is up 216% in the year to date and just reset its record price.

Read more »

Cheerful businessman with a mining hat on the table sitting back with his arms behind his head while looking at his laptop's screen.
Resources Shares

Fortescue shares are galloping again as Twiggy stays confident in China's horsepower

It's business as usual for the miner despite Trump's promised 60% tariffs on Chinese imports.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

How these 3 ASX 200 stocks led the charge higher this week

The three top ASX 200 stocks are up 14% to 34% this week.

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher

These shares are ending the week on a high. But why? Let's find out.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Arcadium Lithium, Block, Jumbo, and Mineral Resources shares

These shares are ending the week in the red. Why are investors selling them?

Read more »